Researchers believe an assay may be used to detect and monitor dynamics of genetic mutations of patients treated with immunotherapy.
The STRIvE-01 study explored the safety of CAR T-cell therapy in children and young adults with relapsed or refractory solid tumors.
Researchers report that the same driving force that makes Zika so detrimental to unborn babies gives it promise as a cancer treatment.
Intravenous Iobenguane I 131 has been approved to treat unresectable, locally advanced, or metastatic pheochromocytoma.
Korean investigators concluded that, in terms of recurrence risk, a qualified high-volume surgeon may be optimal for performing the initial surgery in this setting.
A murine study suggests this engineered combination may offer a major advantage over current CAR T-cell–based immunotherapies.
The CoGAPS gene activity algorithm may elucidate molecular changes that occur as H&N tumors acquire resistance to cetuximab, says a Johns Hopkins team.
Oncologists should refer patients who want traditional genetic counseling and/or have preexisting psychosocial factors that would increase risk of an adverse psychological outcome of counseling.
In analyzing over 8,300 mosaic chromosomal alterations in UK Biobank participants, Harvard researchers uncovered specific alterations that may predict for CLL.
In a large international study, pre-AML cases had greater clonal expansion and enrichment of specific gene mutations; origins of AML were detected > 5 years before it developed.